Why the study?
What is the optimal pharmacologic management of Wolff-Parkinson-White (WPW) syndrome and atrioventricular nodal reentry tachycardia (AVNRT) in infants and children?
Population
Infants and children with Wolff-Parkinson-White syndrome and atrioventricular nodal reentry tachycardia
Design
Review
Authors
Loading...
Supports beta-blockers and digoxin as first-line in pediatric SVT; leaves open need for RCTs to confirm safety and efficacy.
What is the optimal pharmacologic management of Wolff-Parkinson-White (WPW) syndrome and atrioventricular nodal reentry tachycardia (AVNRT) in infants and children?
This review highlights that despite a lack of controlled trials, conventional antiarrhythmics like beta-blockers and digoxin remain first-line for pediatric SVT, with flecainide reserved for refractory cases.
Luedtke et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: